Viridian Therapeutics, Inc. VRDN Stock-Based Comp
Stock-Based Comp at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s stock-based comp?
- Viridian Therapeutics, Inc. (VRDN) reported stock-based comp of $13.39M in Q1 2026.
- How has Viridian Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Viridian Therapeutics, Inc.'s stock-based comp increased by 31.0% year-over-year, from $10.22M to $13.39M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s stock-based comp has grown at a 32.3% compound annual growth rate (CAGR), from $14.47M to $44.3M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.